- Cyclacel Pharmaceuticals (CYCC +3.8%) reviews 2018 achievements and outlines Company’s key business objectives for 2019.
- 2018 Achievements
- CYC065 CDK inhibitor: Initiated a Phase 1 clinical trial evaluating CYC065, a CDK2/9 inhibitor, in combination with venetoclax in patients with relapsed/refractory CLL. Reported data from the Phase 1 part 1 clinical study of CYC065 monotherapy in advanced solid tumors at an oral presentation at the 2018 AACR.
- DNA Damage Response Program: Dosed the first patient in the Phase 1b/2 combination study of sapacitabine in combination with olaparib, in BRCA positive patients with breast cancer.
- CYC140 PLK1 Inhibitor: Completed IND review and initiated patient enrollment for a Phase I study evaluating CYC140 in patients with advanced leukemias.
- Corporate Developments: Entered into a collaboration with The University of Texas MD Anderson Cancer Center to evaluate three Cyclacel medicines in patients with hematological malignancies.
- Key Business Objectives for 2019
- Report initial data readout from the CYC065 plus venetoclax combination Phase 1 study in leukemias, CYC140 Phase 1 study and Combination trial of sapacitabine and olaparib.
- Complete enrollment in part 3 of the Phase 1 study of sequential sapacitabine and seliciclib in BRCA positive, breast, ovarian and pancreatic cancer patients.
- Determine regulatory pathway and submissibility of sapacitabine in elderly AML.
- Evaluate bioequivalence of oral CYC065 formulation to intravenously administered CYC065.
- #JPM19
- Now read: Kala Pharmaceuticals launches INVELTYS
Original article